Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

September 14, 2021; 97 (11) Viewpoint

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

David S. Knopman, Joel S. Perlmutter
First published July 7, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012452
David S. Knopman
From the Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; and Department of Neurology (J.S.P.), Washington University School of Medicine, St. Louis, MO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel S. Perlmutter
From the Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; and Department of Neurology (J.S.P.), Washington University School of Medicine, St. Louis, MO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
David S. Knopman, Joel S. Perlmutter
Neurology Sep 2021, 97 (11) 545-547; DOI: 10.1212/WNL.0000000000012452

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1693

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

The US Food and Drug Administration (FDA) approved aducanumab on June 7, 2021, using an accelerated approval mechanism, based on evidence that aducanumab reduced brain β-amyloid (Aβ) peptide.1 The FDA press release stated that the effect on the surrogate end point “is reasonably likely to predict a clinical benefit to patients…” at some point in the future. As clinical neurologists, we should understand the evidence for this approval and whether this justifies prescribing this medication.

The saga of aducanumab's journey is convoluted.2,-,4 Two phase III studies were initiated in August 2015. They were constructed and executed in an identical manner. In March 2017, the sponsor revised the protocol to allow all participants assigned to the high-dose arm to receive 10 mg/kg. The sponsor conducted a preplanned futility analysis, which led to termination of both studies in March 2019. Three months later, in a surprise press release, the company stated that subsequent analyses with another 3 months of data led them to conclude that there was a sufficient clinical efficacy signal to pursue a new drug application. In follow-up post hoc analyses conducted by the sponsor, one trial (EMERGE or 302) showed statistically significant effects in the high-dose group on several clinical outcome measures; the other study (ENGAGE or 301) showed no benefits.2,3,5,6

We as neurologists need a strategy to advise our patients in this unusual situation where the drug was approved without evidence of consistent clinical benefits. Based on the prescribing information,7 the sponsor shows data from only the positive trial and fails to provide the negative trial's cognitive and functional outcomes. Neurologists should have access to all of the relevant data in these clinical trials; however, they will have to go elsewhere to find it.2,3,5,6 Even choosing to focus on the one trial with the favorable outcome in the high-dose group and ignoring the negative trial, the clinical benefits are decidedly small. The drug never produced substantial improvements. The clinical benefit amounted to about 3 months' worth of delay in decline over a year (annualized Clinical Dementia Rating Scale sum of boxes 0.26 rating points reduction in decline with high-dose aducanumab in the setting of 1.17 points annualized decline in the placebo group). Because our field has not established what constitutes clinical meaningfulness, this benefit could be perceived as having value by some patients and their families. However, this range of delay and progression is well within the untreated variability of groups of patients with mild cognitive impairment (MCI) or dementia due to Alzheimer disease (AD).8 The negative trial, which cannot be brushed under the rug, raises questions about the reliability and reproducibility of any such claimed benefits. The sponsor's presentation at the FDA hearing on November 6, 2020, proposed several post hoc explanations to account for the negative results; however, subjecting the positive trial to post hoc analyses introduced substantial bias and raised serious questions about dose effects and effects on subgroups, as pointed out by the FDA's statistician.9 Combining the results from the 2 trials found no statistically significant clinical benefit for high-dose aducanumab.6 As part of this accelerated approval, the FDA requires Biogen to conduct another prospective clinical trial over the next 9 years to determine whether this drug produces clinical benefit.

The FDA focused on an alternative outcome measure to justify accelerated approval of aducanumab. Rather than relying on a failed clinical end point, the FDA pointed out that the drug lowered brain Aβ, using this biomarker as a surrogate end point. A surrogate outcome measure is reasonable if it predicts clinical benefit. However, no data from either trial or any other source indicate that lowering brain Aβ provides clinical benefit to individuals with AD or when such benefit would occur, if it does. In fact, over the 18-month clinical trials with aducanumab, the FDA explicitly acknowledged no consistent clinical benefit occurred. Several studies demonstrated that lowering Aβ in the brain by inhibition of β- or γ-secretases made patients cognitively worse.10 Furthermore, the change in cognitive performance with aducanumab in the two phase 3 trials did not correlate with the reductions in brain Aβ, as analyzed the FDA's own statistician. In the cardiovascular world, there are many examples of claims based on “sure-thing” biomarker changes that failed to predict eventual clinical benefits.11 Nevertheless, without evidence, lowering Aβ can only hope to be disease-modifying.

Neurologists must also consider the risks, especially in light of the low potential for benefit. Patients with an excess of cortical microbleeds and those on most anticoagulants should not receive aducanumab. Infusion of the recommended monthly doses of aducanumab comes with safety concerns, especially in the form of amyloid-related imaging abnormalities—edema or hemorrhage. With a rate of 40%, and higher in APOE ε4 carriers,5 safety monitoring must be integrated into management. Patients must be able to undergo MRI scans and APOE genotyping for safety reasons. Skilled neuroradiology is also a necessity.

With the above caveats, neurologists then need to determine which patients may be appropriate for aducanumab. With the above caveats, neurologists then need to determine which patients may be appropriate for aducanumab. The original prescribing information7 was revised by the sponsor with approval by the FDA on July 8, 2021 from an apparently very broad indication of “Alzheimer's disease” to a much smaller group of “patients with mild cognitive impairment and mild dementia… the population in which treatment was initiated in clinical trials.”12 The sponsor acknowledged that there is no evidence for treating patients with aducanumab who are either milder than mild cognitive impairment or more impaired than mild dementia, nor is there safety information in those groups. The revised approved indication guides neurologists to avoid prescribing aducanumab to more severely affected patients. There is no evidence for treating patients whose cognitive disorder is jointly attributed to AD and another etiology. Because aducanumab's target is elevated brain Aβ, neurologists must have the available technology to verify that a candidate for aducanumab has elevated brain Aβ. Clinical diagnoses alone are insufficient to verify elevated Aβ.

Aducanumab's approval raises expectations for treatments for patients with symptomatic AD. On the one hand, neurologists want to offer hope. Yet, aducanumab's benefits are meager, if even present,13 and there are nontrivial risks of side effects. These issues place a substantial burden on neurologists to take the time and effort to counsel patients and families on expectations for aducanumab treatment. Neurologists will have to manage therapeutic perceptions by presenting patients and families with unbiased information about the benefits and risks. This is even more challenging as no peer-reviewed publication is available.

Study Funding

The authors report no targeted funding.

Disclosure

D.S. Knopman serves on a Data Safety Monitoring Board for the DIAN study; serves on a Data Safety Monitoring Board for a tau therapeutic for Biogen but receives no personal compensation; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California; has served as a consultant for Roche, Samus Therapeutics, Third Rock, and Alzeca Biosciences but receives no personal compensation; and receives funding from the NIH. J.S. Perlmutter has received research funding from the NIH (NS075321, NS103957, NS107281, NS092865, U10NS077384, NS097437, U54NS116025, U19 NS110456, AG050263, AG-64937, NS097799, NS075527, ES029524, NS109487, R61 AT010753 [NCATS, NINDS, NIA], RO1NS118146, R01AG065214), Department of Defense (DOD W81XWH-217-1-0393), Michael J Fox Foundation, Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson disease research fund), American Parkinson Disease Association (APDA) Advanced Research Center at Washington University, Greater St. Louis Chapter of the APDA, Paula and Rodger Riney Fund, Jo Oertli Fund, Huntington Disease Society of America, Murphy Fund, and CHDI; has received honoraria from CHDI, Huntington Disease Study Group, Parkinson Study Group, Beth Israel Hospital (Harvard group), University of Pennsylvania, and Stanford University; is co-director for the Dystonia Coalition, which has received the majority of its support through the NIH (grants NS116025, NS065701 from the National Institutes of Neurological Disorders and Stroke and TR 001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences); serves as Director of Medical and Scientific Advisory Committee of the Dystonia Medical Research Foundation, Chair of the Scientific Advisory Committee of the Parkinson Study Group, Chair of the Standards Committee of the Huntington Study Group, member of the Scientific Advisory Board of the APDA, Chair of the Scientific and Publication Committee for ENROLL-HD, and member of the Education Committee of the Huntington Study Group; and has provided medical legal consultation to Wood, Cooper and Peterson, LLC, and Simmons and Simmons LLP. D.S. Knopman and J.S. Perlmutter were members of the Peripheral and Central Nervous System Advisory Committee of the Food and Drug Administration but resigned on June 7 and 9, respectively. J.S. Perlmutter participated in the Advisory Committee meeting of November 6, 2020, but D.S. Knopman had been recused from that meeting because he was a site investigator in the aducanumab ENGAGE study. Go to Neurology.org/N for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Editorial, page 517

  • See page 543

  • Received June 16, 2021.
  • Accepted in final form June 22, 2021.
  • © 2021 American Academy of Neurology

References

  1. 1.↵
    1. US Food and Drug Administration
    . FDA grants accelerated approval for Alzheimer’s drug. 2021. Accessed. June 7, 2021. fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
  2. 2.↵
    1. Knopman DS,
    2. Jones DT,
    3. Greicius MD
    . Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17(4):696–701.
    OpenUrl
  3. 3.↵
    1. Kuller LH,
    2. Lopez OL
    . ENGAGE and EMERGE: truth and consequences? Alzheimers Dement. 2021;17(4):692–695.
    OpenUrl
  4. 4.↵
    1. Cummings J,
    2. Aisen P,
    3. Lemere C, et al
    . Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13(1):98.
    OpenUrl
  5. 5.↵
    EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients with Early Alzheimer's Disease. 2019. Accessed December 8, 2019. investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b557697c06f
  6. 6.↵
    1. Lin GA,
    2. Whittington MD,
    3. Synnott PG, et al.
    Aducanumab for Alzheimer's Disease: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review; 2021. Accessed. June 2, 2021. icer.org/assessment/alzheimers-disease-2021/
  7. 7.↵
    Biogen. Prescribing information for Aduhelm. 2021. Accessed. June 7, 2021. accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf.
  8. 8.↵
    1. Jutten RJ,
    2. Sikkes SAM,
    3. Van der Flier WM, et al
    . Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity. Neurology. 2021;96:e2673–e2684.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Massie T
    , BLA 761178 statistical review: aducanumab in Alzheimer’s. 2020. Accessed. June 15, 2021. collaboration.fda.gov/pradgevcxis7.
  10. 10.↵
    1. Egan MF,
    2. Kost J,
    3. Voss T, et al
    . Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med. 2019;380(15):1408-1420.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Echt DS,
    2. Liebson PR,
    3. Mitchell LB, et al
    . Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-788.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Biogen. FDA Approves Updated ADUHELM Prescribing Information to Emphasize Population Studied in Clinical Trials. Accessed July 8, 2021. https://investors.biogen.com/news-releases/news-release-details/fda-approves-updated-aduhelmtm-prescribing-information-emphasize
  13. 13.↵
    1. Liu KY,
    2. Schneider LS,
    3. Howard R
    . The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry. Epub 2021 Jun 1.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • Clinical Efficacy, Drug Safety, and Surrogate EndpointsHas Aducanumab Met All of Its Expectations?
  • Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Editorial
    Clinical Efficacy, Drug Safety, and Surrogate Endpoints
    Has Aducanumab Met All of Its Expectations?
    Linda A. Hershey, Rawan Tarawneh et al.
    Neurology, July 07, 2021
  • Viewpoint
    Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
    Stephen Salloway, Jeffrey Cummings et al.
    Neurology, July 07, 2021
  • Views and Reviews
    Report of the task force on designing clinical trials in early (predementia) AD
    P.S. Aisen, S. Andrieu, C. Sampaio et al.
    Neurology, December 22, 2010
  • Viewpoint
    Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials
    Joshua D. Grill, Jason Karlawish et al.
    Neurology, June 04, 2021
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise